Want to create an interactive transcript for this episode?
Podcast: Surfing the MASH Tsunami
Episode: S3-E54.2 - Presentation on Efruxifermin in NASH with Fibrosis
Description: Last month, Stephen Harrison joined the Surf to cover a recent string of press releases presaging some of the most promising data of the last decade in NASH drug development. As Principal Investigator, he reviewed Phase 2b results from Akero’s HARMONY Trial. This is a 24-week study evaluating the efficacy and safety of the FGF-21 agonist efruxifermin (EFX) in patients with clinically relevant NASH (F2-F3). The topline results he previously shared:The study met its primary endpoint for both the 50mg and 28mg EFX dose groups.Respectively, 41% and 39% of EFX-treated patients experienced at le...